BTL Industries v. DNA Distribution: NMS Device Patent Dispute Settles in 106 Days
BTL Industries, Inc. asserted two patents covering its NMS Body and NMS Face neuromuscular stimulation devices against DNA Distribution, LLC in the Southern District of Florida. The infringement action resolved by settlement in just 106 days — well below the district court median — with a joint stipulation of dismissal ordered by Judge Jacqueline Becerra on May 23, 2025.
NMS Device Maker Reaches Settlement Inside Four Months
BTL Industries, Inc., a medical device company and holder of patents US10478634B2 and US11679255B2 covering neuromuscular stimulation technology embodied in its NMS Body and NMS Face devices, filed suit against DNA Distribution, LLC in the U.S. District Court for the Southern District of Florida on February 6, 2025. The case was assigned to Judge Jacqueline Becerra under Case No. 1:25-cv-20564. BTL’s claim centred on alleged infringement of these two patents by DNA Distribution’s competing or parallel commercialisation of NMS device technology.
The case closed on May 23, 2025, after the parties filed a Notice of Settlement (ECF No. 14). Judge Becerra ordered the parties to submit a Joint Stipulation for Dismissal within 30 days and administratively closed the case, denying all pending motions as moot. The basis of termination is recorded as ‘Case Settled.’ Because the public record does not specify whether dismissal will be with or without prejudice, the operative legal effect on BTL’s right to refile depends on the terms of the forthcoming joint stipulation.
The 106-day resolution is notably swift for a multi-patent infringement action in S.D. Florida and suggests the parties reached commercial alignment early — possibly facilitated by the relative disparity in scale between a medical device innovator and a distribution entity. The specific financial terms, licensing arrangements, or injunctive commitments, if any, remain confidential. What drove settlement at this stage — whether claim construction risk, damages exposure, or commercial negotiation — is not discernible from the public docket.
Filing to Case Settled in 106 days
106 days — notably fast resolution; S.D. Florida median patent case runs well over 2 years
Case settled: what the resolution means for both parties
Settlement via Notice: case administratively closed pending stipulation
The court’s May 23 order was triggered by the parties’ Notice of Settlement, not a merits ruling. Judge Becerra administratively closed the case and directed the parties to file a formal Joint Stipulation for Dismissal within 30 days. The order preserves the right to reopen if settlement completion fails, meaning the case is not yet formally dismissed — only closed for administrative purposes.
No merits adjudicationWith or without prejudice? The public record is silent
The court order does not specify whether the forthcoming dismissal stipulation will be with or without prejudice. This distinction carries significant consequences: a dismissal with prejudice bars BTL from reasserting the same claims against DNA Distribution, whereas without prejudice preserves that right. Until the Joint Stipulation for Dismissal is publicly filed, the operative terms governing BTL’s future enforcement options against this defendant remain unknown.
Prejudice terms undisclosedBTL secures resolution without litigating validity or infringement
BTL Industries avoided the expense and uncertainty of claim construction, expert discovery, and trial. A settlement at this early stage — no substantive motions appear to have been decided — typically suggests the patent holder secured some form of commercial concession from the defendant, whether a licensing arrangement, cessation of infringing activity, or financial settlement. The patents US10478634B2 and US11679255B2 remain unchallenged on the merits.
Patents not invalidatedDNA Distribution exits litigation without an invalidity finding
DNA Distribution resolved the case before any court ruling on infringement or validity. While this avoids the risk of an adverse judgment and potential injunction, it also means no precedent was set limiting BTL’s patents. Depending on settlement terms, DNA Distribution may have accepted licence obligations or agreed to modify its product activities. The absence of any invalidity determination leaves both asserted patents enforceable against other parties in the NMS device sector.
No invalidity findingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BTL Industries, Inc. | Company | Medical device innovator — holder of US10478634B2 and US11679255B2 (NMS devices)Search in Eureka ↗ |
| Defendant | DNA Distribution, LLC | Company | DNA Distribution, LLC — product distribution company accused of NMS device patent infringementSearch in Eureka ↗ |
| Plaintiff counsel | Peter Andrew Koziol | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Assouline & Berlowe PA | Law Firm | Representing BTL Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Scott Dale Smiley. | Attorney | Counsel for DNA Distribution, LLCSearch in Eureka ↗ |
| Defendant law firm | The Concept Law Group | Law Firm | Representing DNA Distribution, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Jacqueline Becerra | Judge | Florida Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a standard administrative settlement closure: no liability was adjudicated, no damages awarded, and no injunction issued. The reference to a forthcoming Joint Stipulation for Dismissal means the legal character of the termination — with or without prejudice — is not yet established by this order alone. The preservation of the right to reopen is a routine procedural safeguard, not an indication of contested terms. Both patents remain presumptively valid and enforceable, with their claim scope untested by the court.
US10478634B2 & US11679255B2 — NMS Body and NMS Face Device Technology
US10478634B2 (application US16/034793) and US11679255B2 (application US17/930888) are U.S. utility patents held by BTL Industries covering neuromuscular stimulation (NMS) technology as embodied in its NMS Body and NMS Face product lines. NMS technology uses externally applied electrical stimulation to induce involuntary muscle contractions, with aesthetic and therapeutic applications. The staggered application numbers suggest a continuation or related family structure, with the later-filed US17/930888 likely extending protection to refined configurations or additional use methods.
The NMS device segment sits at the intersection of medical aesthetics, physiotherapy, and consumer wellness — a market that has attracted significant competitive activity. BTL Industries’ willingness to enforce these patents against a distribution-level defendant signals active portfolio management and suggests the company views its NMS IP as a commercial moat. For competitors developing or distributing body-contouring or facial toning devices involving electrical muscle stimulation, these two patents represent a materially relevant clearance obligation.
Should you run an FTO against US10478634B2 and US11679255B2?
Any company manufacturing, importing, distributing, or commercialising neuromuscular stimulation devices for body or facial applications in the U.S. market should assess clearance against both patents. The fact that BTL pursued a distributor — not only a manufacturer — confirms that channel participants face direct infringement exposure. R&D teams designing EMS or NMS-based aesthetic devices and product managers evaluating U.S. market entry should prioritise these patents in pre-launch FTO reviews.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10478634B2 and US11679255B2 against your device specifications, surface related family members, and flag prosecution history estoppel that may define the scope of enforceable claims. Because both patents share a litigation history without any claim invalidation, Eureka’s prior art analysis and claim differentiation tools are particularly useful for identifying defensible design-around pathways in the NMS device category.
Run a freedom-to-operate analysis on US10478634B2 to assess your product’s exposure
Run FTO in Eureka →Similar NMS and Medical Device Patent Infringement Cases in U.S. District Courts
Cases involving neuromuscular stimulation and medical aesthetic device patents litigated in U.S. district courts, particularly in S.D. Florida and comparable venues.
What this case signals for the NMS device IP landscape
A rapid settlement preserving two unchallenged patents suggests BTL Industries holds meaningful enforcement leverage in the neuromuscular stimulation device market.
Two asserted patents survived intact — enforcement risk remains elevated
Because the case settled without any validity challenge reaching a decision, US10478634B2 and US11679255B2 carry no litigation-tested weaknesses. Any NMS device distributor or manufacturer operating in this space should treat these patents as fully enforceable and factor them into FTO assessments before commercialising competing products.
Swift settlement at 106 days is consistent with early commercial resolution
Infringement cases in S.D. Florida rarely resolve this quickly absent early settlement discussions or demand-letter history predating the filing. The speed here suggests BTL may have a structured enforcement programme and that DNA Distribution calculated settlement as commercially preferable to defending claim construction and discovery. Competitors should monitor BTL’s docket for repeat filings.
BTL v DNA — key questions answered
BTL Industries asserted two patents: US10478634B2 (application US16/034793) and US11679255B2 (application US17/930888), both covering neuromuscular stimulation technology as embodied in its NMS Body and NMS Face devices. Both patents remain unchallenged on the merits following the settlement.
The case resolved after the parties filed a Notice of Settlement on or before May 23, 2025. Judge Becerra ordered a Joint Stipulation for Dismissal to be filed within 30 days and administratively closed the case. The specific financial terms, licensing arrangements, and whether dismissal is with or without prejudice are not disclosed in the public record.
Administrative closure is a procedural step that removes the case from the court’s active docket pending completion of settlement documentation. It does not constitute a final judgment. The case can be reopened upon request if settlement completion fails. The legal finality of the dismissal depends on the forthcoming Joint Stipulation for Dismissal and whether it specifies prejudice terms.
Yes. Because the case settled without any court ruling on validity or infringement, neither patent was invalidated or limited by claim construction. Both US10478634B2 and US11679255B2 remain presumptively valid and fully enforceable against third parties. The settlement creates no precedent constraining BTL’s ability to assert these patents in future actions.
The 106-day resolution is notably swift for a multi-patent infringement case in S.D. Florida. While the precise reasons are not in the public record, the speed is consistent with pre-litigation demand-letter negotiations, a significant commercial or scale disparity between the parties, or an early calculus by DNA Distribution that settlement was preferable to the cost and risk of defending patent validity and infringement through discovery and trial.
PatSnap Eureka searches patents and litigation data to answer instantly.